Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07119775) titled 'Tideglusib: Expanded Access Use in Congenital Myotonic Dystrophy' on Aug. 6.
Study Type: Expanded Access
Primary Sponsor: AMO Pharma Limited
Condition:
Congenital Myotonic Dystrophy
Intervention:
Drug: Tideglusib
Recruitment Status: Not recruiting
Date of First Enrollment: August 1, 2025
To know more, visit https://clinicaltrials.gov/ct2/show/NCT07119775
Published by HT Digital Content Services with permission from Health Daily Digest....